Identification of candidate agents with higher drug sensitivity in high-PPS score patients. (A) A venn diagram for summarizing included compounds from CTRP and PRISM datasets (see also Table S12 available online at https://dbpia.nl.go.kr/bib). (B) Volcano plot of differential expression between bulk HCC samples and hepatoma cell lines (Wilcoxon rank-sum test: adjust P < 0.05, and log2FC > 1). Stroma markers are highlighted in deep colour (see also Table S13 available online at https://dbpia.nl.go.kr/bib). (C) Volcano plot of differential expression between purified HCC samples and hepatoma cell lines (Wilcoxon rank-sum test: adjust P < 0.05, and log2FC > 1). Stroma markers are highlighted in deep color (see also Table S13 available online at https://dbpia.nl.go.kr/bib). (D) Comparison of estimated sorafenib’s sensitivity (logAUC) between PI3K-MTOR altered and unaltered groups. (E) Schematic outlining the strategy to identify agents with higher drug sensitivity in high PPS score patients. (F) The results of Spearman’s correlation analysis and differential drug response analysis of six CTRP-derived compounds. (G) The results of Spearman’s correlation analysis and differential drug response analysis of six PRISM-derived compounds. Note that lower values on the y-axis of boxplots imply greater drug sensitivity.